Cytokine expression of transforming growth factor-β2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels;Expression der immunsupprimierenden zytokine TGF-β2 und II-10 in Kopf- Hals-Tumoren vergleich von serumwerten und gewebeexpression

HNO

Volumn 47, Issue 10, 1999, Pages 879-884

  Karcher, J ^a   Reisser, Ch ^b   Daniel, V ^b   Herold Mende, Christel ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b NONE

Author keywords

Cytokines; Head and neck tumor; Immunocytochemistry; Tumor induced immunosuppression

Indexed keywords

INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER STAGING; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; BIOPSY; BLOOD; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK TUMOR; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPH NODE; LYMPH NODE METASTASIS; PATHOLOGY;

BIOPSY; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-10; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032585977     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001060050528     Document Type: Article

References (20)

1. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT (1993) Antitransforming growth factor beta antibodies inhibit breast cancer cell tumorignicity and incrase mouse spleen natural killer cell activity. J Clin Invest 92: 2569-2576
2. Avradopoulos K, Mehta S, Blackinton D, Wanebo HJ (1997) Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol 4: 184-190
3. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R (1995) Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 85: 2516-2520
4. Fakhrai H, Dorigo O, Shawler DL et al. (1996) Eradication of established intracranial rat gliomas by tranfoming growth factor beta antisense gen therapy. Proc Natl Acad Sci USA 93: 2909-2914
5. Gastl GA, Abrams JS, Nanus DM et al. (1993) Interleukin-10 production by human carcinoma cell lines and it's relation ship to interleukin-6 expression. Int J Cancer 55: 96-101
6. Herold-Mende C, Seiter S, Born AI et al. (1996) Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J Pathol 179: 66-73
7. Hishii M, Nitta T, Ishida H et al. (1995) Human glioma-derived interleukin-10 inhibits antitumor immune response in vitro. Neurosurgery 37: 1160-1166
8. Hoefer M, Anderer FA (1995) Anti-(TGF-beta) antibodies with predefined specifity inhibit metastasis of highly tumorigenic human xenotranplants in nu/nu mice. Cancer Immunol 41: 302-308
9. Jasani B, Wyllie PA, Lemoine NR, Williams ED, Wynforf-Thomas D (1990) Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 2: 149
10. Kong FM, Anscher MS, Murase T, Abbott BD, Inglehart JD, Jirtle RL (1995) Elevated plasma tgf-β1 levels in breast cancer patients decreas after surgical removal of the tumor. Ann Surg 222: 155-162
11. Kopp A, Jonat W, Schmahl, M, Knabbe C (1995) Transforming growth factor beta 2 (TGF-β2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55: 4512-4516
12. Lawrence DA (1996) Transforming growth factor-β: a general review. Eur Cytokine Netw 7: 363-374
13. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN (1992) Effect of expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76: 799-804
14. Penn I (1995) Principles of tumor immunity: immunocompetence and cancer. In: DeVita VT, Rosenberg SA (eds) Biologic therapy of cancer: principles and practice, vol 6. Saunders, Philadelphia, pp 103-118
15. Rennick D, Berg D, Holland G (1992) Interleukin 10: an overview. Prog Growth Factor Res 4: 207-227
16. Tada T, Ohzeki S, Utsumi K at al. (1991) Transforming growth factor-β-induced inhibition of T cell function. J Immunol 146: 1077-1082
17. Toth A, Alfoldy F, Jary J, Hidvegi M, Perner F (1992-93) Malignant tumors after renal transplantation. Acta Chir Hung 33: 211-216
18. Wojotowicz-Praga S (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20: 165-177
19. Wright JA, Turley E, Greenberg AH (1993) Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy. Crit Rev Oncol 4: 473-492
20. Young RI, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM (1996) Mechanisms of immune suppression in patients with head and neck cancer: influence on the infiltrate of the cancer. Int J Cancer 67: 333-338